Navigation Links
The Atherothrombotic Diseases Market Will Increase from $36 Billion in 2012 to $47 Billion in 2022
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies for the treatment of coronary heart disease, peripheral arterial disease and ischemic stroke and transient ischemic attack) will drive the market to increase from $36 billion in 2012 to $47 billion in 2022. The launch of several premium-priced add-on therapies will offset the generic erosion of key brands and drive significant market growth during the second half of the study period (2017-2022).

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The much-anticipated arrival of two antidyslipidemic drug classes, the cholesteryl ester transfer protein (CETP) inhibitors and the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, is expected to begin in 2017, with the launch of Eli Lilly's CETP inhibitor evacetrapib. With morbidity and mortality data available at launch, Decision Resources expects rapid uptake of these agents as add-on therapies, particularly in high-risk patients, significantly contributing to market growth from 2017 to 2022.

"Interviewed thought leaders are very excited about the potential of the emerging PCSK9 inhibitor drug class," said Decision Resources Senior Director Conor Walsh, Ph.D. "The clinical profile from Phase II data has been promising, combining strong reductions in LDL-C on top of statin therapy with an apparently good safety and tolerability profile. Although their injectable nature and anticipated high price will limit widespread use, we believe blockbuster status is achievable."

The Pharmacor advisory service report entitled Atherothrombotic Diseases, which will be published in the days ahead, finds that despite reductions in risk due to improved public health measures and primary prophylaxis, the number of diagnosed prevalent cases of atherothrombotic disease will rise steadily during the forecast period, driven by improvements in post-acute coronary syndrome and post-stroke survival, a greater proportion of cases being diagnosed and aging populations. This rise, along with the launch of high-priced add-on therapies, will boost the value of the atherothrombotic diseases market.

The report also finds that the overall value of the antithrombotic agent market will benefit from the expansion of current, premium-priced, oral antithrombotic agents, such as AstraZeneca's Brilinta/Brilique and Bayer/Janssen's Xarelto, into new indications, further eroding the dominance of clopidogrel (Bristol-Myers Squibb/Sanofi's Plavix/Iscover, generics). Further support will come from the launch of Merck's vorapaxar for the treatment of post-myocardial infarction patients.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
2. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
3. Alzheimers Drug Discovery Foundation Expands its ADDF ACCESS Program to Improve Quality and Efficiency of Drug Research for Neurodegenerative Diseases
4. Rheumatology Network Presents Latest Advances Against Baffling Inflammatory Diseases From Major Rheumatology Conference
5. Harrisvaccines, Inc. Secures Exclusive Rights From AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals
6. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
7. Warnings for Hepatitis B Reactivation in Cancer Patients Welcomed by the American Association for the Study of Liver Diseases
8. Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases
9. Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
10. Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients
11. Aptel Research Launches Unique Patient-centric Syndicated Report Series That Analyze the Patient Journey for Chronic Diseases in Specialty Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... SHANGHAI , Jan. 18, 2017 In ... of revolution, which is where the Upgrade of ... year of the 13th Five-Year Plan for Economic and Social ... (the 13th Five-Year Plan), and the state council of ... the "13th Five-Year" national strategic emerging industry development plan, identifying ...
(Date:1/18/2017)... Invetech, the leading developer of ... , has announced a collaboration agreement with Erytech ... treatments for acute leukemia and other oncology indications ... will develop systems to enable the commercial-scale manufacture ... platform, which uses a novel technology to encapsulate ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
Breaking Medicine Technology:
(Date:1/18/2017)... KS (PRWEB) , ... January 18, 2017 , ... ... firm offering asset protection and financial planning services to families and business owners ... charity event aimed at supporting children with developmental disabilities. , The Lakemary Center ...
(Date:1/18/2017)... ... January 18, 2017 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that Mr. Michael Merges, Director of Strategic Growth, ... be held at the Mayflower Hotel, Washington DC, on Jan. 24 – 26, ...
(Date:1/18/2017)... Lebanon, NH (PRWEB) , ... January 18, 2017 ... ... the launch of the revolutionary Active Brake Technology (ABT), an innovative braking system ... stability. , Active Brake Technology addresses one of the biggest concerns of beginner ...
(Date:1/17/2017)... ... ... January is National Stalking Awareness Month (NSAM), now in its fourteenth year, when ... the crime of stalking, a very real danger to many in our community. We ... and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads the theme for ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... point of difference. Eden Activewear is a stand-out company for several differences from ... online and only manufacture on demand, this is called 'Agile' manufacturing - ...
Breaking Medicine News(10 mins):